OptiNose, Inc. (NASDAQ:OPTN) Stake Decreased by Stonepine Capital Management LLC

Stonepine Capital Management LLC lowered its stake in OptiNose, Inc. (NASDAQ:OPTN - Free Report) by 89.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 588,657 shares of the company's stock after selling 5,099,933 shares during the period. OptiNose comprises 3.2% of Stonepine Capital Management LLC's investment portfolio, making the stock its 8th biggest position. Stonepine Capital Management LLC owned approximately 5.85% of OptiNose worth $3,932,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Acorn Capital Advisors LLC acquired a new stake in shares of OptiNose during the 4th quarter worth about $2,824,000. 85.60% of the stock is owned by hedge funds and other institutional investors.

OptiNose Stock Down 0.4%

OPTN traded down $0.04 during trading on Wednesday, hitting $9.67. 860,900 shares of the stock were exchanged, compared to its average volume of 62,708. The firm has a market capitalization of $97.97 million, a P/E ratio of -2.30 and a beta of -0.88. OptiNose, Inc. has a 1-year low of $4.82 and a 1-year high of $20.03. The stock has a fifty day moving average price of $9.06 and a two-hundred day moving average price of $7.45.

OptiNose (NASDAQ:OPTN - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.27). The business had revenue of $18.51 million during the quarter, compared to the consensus estimate of $17.70 million. Analysts predict that OptiNose, Inc. will post -3.22 EPS for the current year.

Insider Buying and Selling at OptiNose

In related news, CEO Ramy A. Mahmoud sold 6,376 shares of OptiNose stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $5.29, for a total value of $33,729.04. Following the sale, the chief executive officer now directly owns 126,931 shares in the company, valued at $671,464.99. The trade was a 4.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders have sold 8,213 shares of company stock worth $43,643. 2.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Piper Sandler reissued a "neutral" rating and set a $9.00 target price (down previously from $15.00) on shares of OptiNose in a research report on Friday, March 21st. Lake Street Capital lowered OptiNose from a "buy" rating to a "hold" rating and cut their target price for the stock from $17.00 to $9.00 in a research report on Thursday, March 20th. Finally, HC Wainwright reissued a "neutral" rating and set a $9.00 target price on shares of OptiNose in a research report on Monday.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.